Liévin R, Burroni B, Balducci E, Palmic P, Decroocq J, Deau-Fischer B, Franchi P, Vignon M, Zerbit J, Cottereau A S, Touzart A, Villarese P, Kaltenbach S, Lhermitte L, Asnafi V, Bouscary D, Willems L
Clinical Hematology Department, AP-HP, Hôpital Cochin, Université de Paris, Paris, France.
Laboratory of Molecular Mechanisms of Hematological Disorders and Therapeutic Implications, INSERM U 1163, Institut Imagine, Paris, France.
Eur J Haematol. 2025 Jan;114(1):186-194. doi: 10.1111/ejh.14325. Epub 2024 Oct 12.
Primary testicular lymphoma (PTL) is a rare occurrence of diffuse large B-cell lymphoma (DLBCL) that accounts for 1%-2% of all cases. Nodal DLBCL with testis involvement (DLBCL-T) and PTL are associated with poor prognosis, with high incidence of central nervous system relapse. Fifteen patients (median age 60 years) with PTL (n = 5) or DLBCL-T (n = 10) received high-dose methotrexate + R-CHOP. Overall, complete response (CR) rate was 73% and overall response rate 86%. With a 3.9-year median follow-up, 100% of patients with PTL had CR and none relapsed. On the contrary, 55% of DLBCL-T patients achieved CR among which only one was still in remission at the end of follow-up. Molecular parallels between PTL and Primary CNS Lymphoma (PCNSL) suggest shared origins, urging further research for tailored treatments and enhanced understanding of these lymphomas' biology.
原发性睾丸淋巴瘤(PTL)是弥漫性大B细胞淋巴瘤(DLBCL)的一种罕见形式,占所有病例的1%-2%。伴有睾丸受累的结内DLBCL(DLBCL-T)和PTL预后较差,中枢神经系统复发率高。15例(中位年龄60岁)PTL(n = 5)或DLBCL-T(n = 10)患者接受了大剂量甲氨蝶呤+R-CHOP治疗。总体而言,完全缓解(CR)率为73%,总缓解率为86%。中位随访3.9年,PTL患者的CR率为100%,无复发。相反,DLBCL-T患者中有55%达到CR,其中随访结束时只有1例仍处于缓解状态。PTL与原发性中枢神经系统淋巴瘤(PCNSL)之间的分子相似性表明它们有共同的起源,这促使人们进一步研究针对性治疗方法,并加深对这些淋巴瘤生物学特性的理解。